The AMYPAD Diagnostic and Patient Management Study (DPMS) aims at better understanding the impact of the utilisation of amyloid PET imaging on diagnostic thinking and patient management. AMYPAD will scan a large population cohort (n=900) suspected of possible Alzheimer’s disease (AD).
The AMYPAD DPMS recently hit a significant milestone as the study has already recruited more than half of the research participants needed to fulfil its goal. The study is fully activated in eight sites including Geneva (Switzerland), Amsterdam (Netherlands), Toulouse (France), Barcelona (Spain), London (UK), Cologne (Germany), Stockholm (Sweden) and Lausanne (Switzerland), with a total of 606 research participants at the end of November 2019. Moreover, this achievement was recently followed by more positive news. Indeed, October 2019 was the best month for recruitment ever, with 60 participants enrolled (the average of the previous six months was 41).
This positive trend, together with the recent activation of the last site in Stockholm, gives hope that the enrolment will be finishing during the first half of 2020. While participant recruiting is going relatively well, the data management activities have also been started to ensure a clean dataset for the next step of data analysis. The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.
